

# CV Sciences Certificate of Analysis



*This document is to certify that units of the lot number below were tested and found to comply with CV Sciences finished product specifications.*

PRODUCT NAME:	SAMPLE ID:
Strength:	Expiration Date:
Lot Number:	Total Quantity Produced:

PHYSICAL PROPERTIES	STATUS (PASS/FAIL)	METHOD
Appearance		
Color		
Aroma		

CANNABINOIDS*	MG/UNIT	METHOD
CBD		
CBDA		
d9-THC		
THCA-A		
d8-THC		
THCV		
CBDV		
CBDVA		
CBGA		
CBG		
CBN		
CBC		
CBL		
Total Cannabinoids		
Unit Weight		
THC by Mass		

OTHER ACTIVE INGREDIENTS**	MG/UNIT	METHOD
Palmitoylethanolamide (PEA)		

HEAVY METALS*	STATUS (PASS/FAIL)	METHOD
Arsenic		
Cadmium		
Mercury		
Lead		

# CV Sciences Certificate of Analysis



MICROBIOLOGY*	STATUS (PASS/FAIL)	METHOD
Mold/Mildew/Yeast		
Aerobic Bacteria		
Coliforms		
E. Coli		
Salmonella		
Pseudomonas		

PESTICIDES***	STATUS (PASS/FAIL)	METHOD
Total Pesticides		

RESIDUAL SOLVENTS***	STATUS (PASS/FAIL)	METHOD
Total Residual Solvents		

1. The hemp extract is the product of a batch tested by the independent testing laboratory;
2. The batch contained a total delta-9-tetrahydrocannabinol concentration that did not exceed 0.3 percent pursuant to the testing of random sample of the batch; and
3. The batch does not contain contaminants unsafe for human consumption.<sup>†</sup>

<sup>†</sup>Tested analytes and limits were set by CV Sciences, Inc.

DB Labs Sample ID #:

\*Actual analytical results obtained by DB Labs (Las Vegas, NV), CV Sciences' third-party testing laboratory.



Advanced Botanical Consulting & Testing Sample ID #:

\*\*Actual analytical results obtained by Advanced Botanical Consulting & Testing, Inc. (Tustin, CA), CV Sciences' third-party testing laboratory.

Anresco Laboratories Sample ID #:

\*\*\*Actual analytical results obtained by Anresco Laboratories (San Francisco, CA), CV Sciences' third-party testing laboratory.

*This Certificate of Analysis has been generated to document product test results.  
The "Prepared By" signature does not indicate finished product release for distribution.*

QUALITY APPROVAL		
Prepared By / Date	Approved By / Date	Status
Vandana Kothari	<div><div> Signed by Vandana Kothari</div><div> I approve this document 19-May-2025   10:40 PDT 87A410FFF03248738900BEE0D0868E359</div></div>	PASS




May 12, 2025

**CV SCIENCES, INC.**9530 Padgett Street, Suite 107  
San Diego, CA 92126Order No. 571693  
Sample No. 1303434

## SAMPLE INFORMATION

**Description** FP-25-0041 plusCBD Relief softgels 60ct SKU 608 exp 03/27  
**Lot Number** 52644  
**Category (Type)** Non-Inhalable Edible (Capsule)  
**Received** May 09, 2025

## ANALYTICAL RESULTS


**Analysis** Cannabinoid Profile (Non-Plant)  **Pass**  
**Instrument** Liquid Chromatography Diode Array Detector (LC-DAD)  
**Method** MF-CHEM-15  
**Analysis Date** May 10, 2025 to May 12, 2025

Cannabinoid	mg/g	%	mg/serving	mg/package	Status
Δ8-THC	ND	ND	ND	ND	-
Δ9-THC	ND	ND	ND	ND	Pass
Δ9-THCA	ND	ND	ND	ND	-
THCV	ND	ND	ND	ND	-
THCVA	ND	ND	ND	ND	-
CBD	21.83	2.183	17.72	1063.36	-
CBDA	19.39	1.939	15.74	944.43	-
CBC	ND	ND	ND	ND	-
CBCA	ND	ND	ND	ND	-
CBDV	<LOQ	<LOQ	<LOQ	<LOQ	-
CBG	0.42	0.042	0.34	20.63	-
CBGA	<LOQ	<LOQ	<LOQ	<LOQ	-
CBN	ND	ND	ND	ND	-
Total THC	ND	ND	ND	ND	-
Total CBD	38.84	3.884	31.53	1891.63	-
Total Cannabinoids	39.26	3.926	31.87	1912.25	-
Sum of Cannabinoids	41.64	4.164	33.81	2028.42	-
<b>Serving Weight (g)</b>	0.8118				
<b>Package Weight (g)</b>	48.708				

**Comments**

Reported results and measurements are based off of a calculated hypothetical weight using the ratio between filling weight and total capsule weight as per client instruction. Only the filling material was tested.

Reported by  
**Anresco, Inc.**

  
Donald Lao  
Analyst II

May 12, 2025



NT = Not Tested  
ND = None Detected  
LOD = Limit of Detection ( 0.1333 mg/g)  
LOQ = Limit of Quantitation ( 0.4000 mg/g)  
Total THC = Δ8-THC + Δ9-THC + (0.877 \* THCA)  
Total CBD = CBD + (0.877 \* CBDA)  
Total Cannabinoids = Σ (neutral cannabinoids) + [0.877 \* Σ (acidic cannabinoids)]

If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".

May 14, 2025

**CV SCIENCES, INC.**9530 Padgett Street, Suite 107  
San Diego, CA 92126

Order No. 571693

Sample No. 1303434

## SAMPLE INFORMATION

**Description** FP-25-0041 plusCBD Relief softgels 60ct SKU 608 exp 03/27  
**Lot Number** 52644  
**Category (Type)** Non-Inhalable Edible (Capsule)  
**Received** May 09, 2025

## ANALYTICAL RESULTS

**Analysis** Pesticide Screen ✔ Pass  
**Instrument** Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)  
**Method** MF-CHEM-13  
**Analysis Date** May 10, 2025 to May 14, 2025

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.017/0.05	ND	5.0	Pass
Aldicarb	0.02/0.06	ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0.2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.017/0.05	ND	0.017	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.06	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0.30	ND	1.0	Pass
Cypermethrin	0.10/0.30	ND	1.0	Pass
Daminozide	0.017/0.05	ND	0.017	Pass
DDVP (Dichlorvos)	0.013/0.04	ND	0.013	Pass
Diazinon	0.017/0.05	ND	0.2	Pass
Dimethoate	0.017/0.05	ND	0.017	Pass
Dimethomorph	0.017/0.05	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.017/0.05	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass

If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".

# Certificate of Analysis

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Fipronil	0.02/0.06	ND	0.02	Pass
Flonicamid	0.02/0.06	ND	2.0	Pass
Fludioxonil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.017/0.05	ND	5.0	Pass
Metalaxyl	0.017/0.05	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.013/0.04	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.017/0.05	ND	0.5	Pass
Oxamyl	0.013/0.04	ND	0.2	Pass
Paclobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.017/0.05	ND	0.2	Pass
Permethrins	0.10/0.30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
Piperonyl Butoxide	0.017/0.05	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.02/0.06	ND	20.0	Pass
Propoxur	0.013/0.04	ND	0.013	Pass
Pyrethrins	0.15/0.50	ND	1.0	Pass
Pyridaben	0.017/0.05	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.017/0.05	ND	0.017	Pass
Tebuconazole	0.02/0.06	ND	2.0	Pass
Thiacloprid	0.013/0.04	ND	0.013	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass
Trifloxystrobin	0.02/0.06	ND	30.0	Pass

Reported by  
**Anresco, Inc.**

NT = Not Tested  
 ND = None Detected  
 LOD = Limit of Detection  
 LOQ = Limit of Quantitation

Seonmin Lee  
 Analyst II



May 14, 2025

If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".

May 14, 2025

**CV SCIENCES, INC.**9530 Padgett Street, Suite 107  
San Diego, CA 92126

Order No. 571693

Sample No. 1303434

## SAMPLE INFORMATION

**Description** FP-25-0041 plusCBD Relief softgels 60ct SKU 608 exp 03/27  
**Lot Number** 52644  
**Category (Type)** Non-Inhalable Edible (Capsule)  
**Received** May 09, 2025

## ANALYTICAL RESULTS

**Analysis** Residual Solvent Screen ✔ Pass  
**Instrument** Gas Chromatography Mass Spectrometry (GC/MS)  
**Method** MF-CHEM-32  
**Analysis Date** May 10, 2025 to May 14, 2025

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0.5/0.5	ND	1	Pass
Acetone	57/200	ND	5000	Pass
Acetonitrile	56/200	ND	410	Pass
Benzene	0.5/0.5	ND	1	Pass
n-Butane	45/200	ND	5000	Pass
Chloroform	0.5/0.5	ND	1	Pass
Ethanol	37/200	ND	5000	Pass
Ethyl acetate	38/200	ND	5000	Pass
Ethyl ether	37/200	ND	5000	Pass
Ethylene oxide	0.1/0.5	ND	1	Pass
n-Heptane	135/200	ND	5000	Pass
n-Hexane	49/200	ND	290	Pass
Isopropyl alcohol	57/200	ND	5000	Pass
Methanol	37/200	ND	3000	Pass
Methylene chloride	0.1/0.5	ND	1	Pass
n-Pentane	37/200	ND	5000	Pass
Propane	72/200	ND	5000	Pass
Toluene	49/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	58/200	ND	2170	Pass
Trichloroethylene	0.5/0.5	ND	1	Pass

Reported by  
**Anresco, Inc.**

NT = Not Tested  
ND = None Detected  
LOD = Limit of Detection  
LOQ = Limit of Quantitation

Alma Dorantes  
Analyst I



May 14, 2025

If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".



# Certificate of Analysis

May 14, 2025

**CV SCIENCES, INC.**  
9530 Padgett Street, Suite 107  
San Diego, CA 92126

Order No. 571693  
Sample No. 1303434

## SAMPLE INFORMATION

**Description** FP-25-0041 plusCBD Relief softgels 60ct SKU 608 exp 03/27  
**Lot Number** 52644  
**Category (Type)** Non-Inhalable Edible (Capsule)  
**Received** May 09, 2025

## ANALYTICAL RESULTS

**Analysis** Mycotoxins Screen ✔ Pass  
**Instrument** Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)  
**Method** MF-CHEM-13  
**Analysis Date** May 10, 2025 to May 14, 2025

Analyte	LOD/LOQ (ppb)	Findings (ppb)	Limit (ppb)	Status
Aflatoxin B1	2/5	ND	-	-
Aflatoxin B2	2/5	ND	-	-
Aflatoxin G1	2/5	ND	-	-
Aflatoxin G2	2/5	ND	-	-
Total Aflatoxins	8/20	ND	20	Pass
Ochratoxin A	6/18	ND	20	Pass

Reported by  
**Anresco, Inc.**

NT = Not Tested  
ND = None Detected  
LOD = Limit of Detection  
LOQ = Limit of Quantitation

1/14/25  
Seonmin Lee  
Analyst II  
May 14, 2025



If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".

May 18, 2025

**CV SCIENCES, INC.**

9530 Padgett Street, Suite 107  
San Diego, CA 92126

Order No. 571693  
Sample No. 1303434

## SAMPLE INFORMATION

Description FP-25-0041 plusCBD Relief softgels 60ct SKU 608 exp 03/27  
Lot Number 52644  
Received May 09, 2025

## ANALYTICAL RESULTS

Analysis Date May 10, 2025 to May 18, 2025

Findings	Analysis	Results	Method
	Standard Plate Count	<10 cfu/g	FDA BAM
	Yeast	<10 cfu/g	FDA BAM
	Mold	<10 cfu/g	FDA BAM
	Coliforms	<10 cfu/g	FDA BAM - ECC AGAR
	Escherichia coli	<10 cfu/g	FDA BAM - ECC AGAR
	Salmonella	Negative /10g	MF-MICRO-11 (AOAC 2016.01)
	Staph aureus	Negative /10g	USP <62>

Reported by  
**Anresco, Inc.**



Allen Zhu  
Analyst

If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".

page 1 of 1



May 14, 2025

**CV SCIENCES, INC.**

9530 Padgett Street, Suite 107  
San Diego, CA 92126

Order No. 571693  
Sample No. 1303434

## SAMPLE INFORMATION

**Description** FP-25-0041 plusCBD Relief softgels 60ct SKU 608 exp 03/27  
**Lot Number** 52644  
**Category (Type)** Non-Inhalable Edible (Capsule)  
**Received** May 09, 2025

## ANALYTICAL RESULTS

**Analysis** Heavy Metals ✔ Pass  
**Instrument** Inductively Coupled Plasma Mass Spectrometry (ICP-MS)  
**Method** MF-CHEM-16  
**Analysis Date** May 10, 2025 to May 14, 2025

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Arsenic	0.003/0.05	ND	1.5	Pass
Cadmium	0.008/0.05	ND	0.5	Pass
Mercury	0.002/0.05	ND	3	Pass
Lead	0.01/0.125	ND	0.5	Pass

Reported by  
**Anresco, Inc.**

NT = Not Tested  
ND = None Detected  
LOD = Limit of Detection  
LOQ = Limit of Quantitation



Eric Tam  
Senior Chemist

May 14, 2025

If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".

## Certificate Of Completion

Envelope Id: 7CD08EFF-5791-4341-BF8B-A42E17A07058

Status: Completed

Subject: FP-25-0041 plusCBD Relief softgels 60ct COA.pdf

Source Envelope:

Document Pages: 9

Signatures: 1

Envelope Originator:

Certificate Pages: 1

Initials: 0

Vandana Kothari

AutoNav: Enabled

vandana.kothari@cvsciences.com

Envelopeld Stamping: Enabled

IP Address: 64.207.219.135

Time Zone: (UTC-08:00) Pacific Time (US & Canada)

## Record Tracking

Status: Original

Holder: Vandana Kothari

Location: DocuSign

5/19/2025 10:37:44 AM

vandana.kothari@cvsciences.com

## Signer Events

## Signature

## Timestamp

Vandana Kothari

vandana.kothari@cvsciences.com

DIRECTOR OF QUALITY

CV Sciences - Part 11

Security Level: Email, Account Authentication  
(Required)

*Vandana Kothari*

Signature Adoption: Pre-selected Style

Signature ID:

87A410FF-F032-4873-8900-BEED0868E359

Using IP Address: 75.85.176.253

Sent: 5/19/2025 10:38:29 AM

Viewed: 5/19/2025 10:39:35 AM

Signed: 5/19/2025 10:40:19 AM

With Signing Authentication via Docusign password

With Signing Reasons (on each tab):

I approve this document

## Electronic Record and Signature Disclosure:

Not Offered via Docusign

## In Person Signer Events

## Signature

## Timestamp

## Editor Delivery Events

## Status

## Timestamp

## Agent Delivery Events

## Status

## Timestamp

## Intermediary Delivery Events

## Status

## Timestamp

## Certified Delivery Events

## Status

## Timestamp

## Carbon Copy Events

## Status

## Timestamp

## Witness Events

## Signature

## Timestamp

## Notary Events

## Signature

## Timestamp

## Envelope Summary Events

## Status

## Timestamps

Envelope Sent

Hashed/Encrypted

5/19/2025 10:38:29 AM

Certified Delivered

Security Checked

5/19/2025 10:39:35 AM

Signing Complete

Security Checked

5/19/2025 10:40:19 AM

Completed

Security Checked

5/19/2025 10:40:19 AM

## Payment Events

## Status

## Timestamps